CYTK Long Call Strategy
CYTK (Cytokinetics, Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK (Cytokinetics, Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $9.61B, a beta of 0.38 versus the broader market, a 52-week range of 29.31-80.2, average daily share volume of 2.5M, a public-listing history dating back to 2004, approximately 498 full-time employees. These structural characteristics shape how CYTK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.38 indicates CYTK has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on CYTK?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current CYTK snapshot
As of May 15, 2026, spot at $75.91, ATM IV 49.30%, IV rank 2.71%, expected move 14.13%. The long call on CYTK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on CYTK specifically: CYTK IV at 49.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a CYTK long call, with a market-implied 1-standard-deviation move of approximately 14.13% (roughly $10.73 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CYTK expiries trade a higher absolute premium for lower per-day decay. Position sizing on CYTK should anchor to the underlying notional of $75.91 per share and to the trader's directional view on CYTK stock.
CYTK long call setup
The CYTK long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CYTK near $75.91, the first option leg uses a $75.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CYTK chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CYTK shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $75.00 | $5.25 |
CYTK long call risk and reward
- Net Premium / Debit
- -$525.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$525.00
- Breakeven(s)
- $80.25
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CYTK long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CYTK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$525.00 |
| $16.79 | -77.9% | -$525.00 |
| $33.58 | -55.8% | -$525.00 |
| $50.36 | -33.7% | -$525.00 |
| $67.14 | -11.6% | -$525.00 |
| $83.93 | +10.6% | +$367.51 |
| $100.71 | +32.7% | +$2,045.81 |
| $117.49 | +54.8% | +$3,724.11 |
| $134.27 | +76.9% | +$5,402.41 |
| $151.06 | +99.0% | +$7,080.71 |
When traders use long call on CYTK
Long calls on CYTK express a bullish thesis with defined risk; traders use them ahead of CYTK catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CYTK thesis for this long call
The market-implied 1-standard-deviation range for CYTK extends from approximately $65.18 on the downside to $86.64 on the upside. A CYTK long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CYTK IV rank near 2.71% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CYTK at 49.30%. As a Healthcare name, CYTK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CYTK-specific events.
CYTK long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CYTK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CYTK alongside the broader basket even when CYTK-specific fundamentals are unchanged. Long-premium structures like a long call on CYTK are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CYTK chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CYTK?
- A long call on CYTK is the long call strategy applied to CYTK (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CYTK stock trading near $75.91, the strikes shown on this page are snapped to the nearest listed CYTK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CYTK long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CYTK long call priced from the end-of-day chain at a 30-day expiry (ATM IV 49.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$525.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CYTK long call?
- The breakeven for the CYTK long call priced on this page is roughly $80.25 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CYTK market-implied 1-standard-deviation expected move is approximately 14.13%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CYTK?
- Long calls on CYTK express a bullish thesis with defined risk; traders use them ahead of CYTK catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CYTK implied volatility affect this long call?
- CYTK ATM IV is at 49.30% with IV rank near 2.71%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.